Next Article in Journal
Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
Next Article in Special Issue
Palliative Electrochemotherapy in Vulvar Carcinoma: Preliminary Results of the ELECHTRA (Electrochemotherapy Vulvar Cancer) Multicenter Study
Previous Article in Journal
Combined Targeting of Estrogen Receptor Alpha and XPO1 Prevent Akt Activation, Remodel Metabolic Pathways and Induce Autophagy to Overcome Tamoxifen Resistance
Previous Article in Special Issue
Increase Paclitaxel Sensitivity to Better Suppress Serous Epithelial Ovarian Cancer via Ablating Androgen Receptor/Aryl Hydrocarbon Receptor-ABCG2 Axis
Open AccessArticle

Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma

1
QST Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan
2
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi 371-8511, Japan
3
Department of Radiology, Jichi Medical University, Tochigi 329-0498, Japan
4
Department of Radiation Oncology, Saitama Medical University International Medical Center, Saitama 350-1298, Japan
5
Department of Radiation Oncology, Japanese Red Cross Maebashi Hospital, Maebashi 371-0811, Japan
6
Department of Radiation Oncology, Tokyo Women’s Medical University School of Medicine, Tokyo 162-8666, Japan
7
Department of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba 260-8677, Japan
*
Author to whom correspondence should be addressed.
These authors contributed equally to this study.
Cancers 2019, 11(4), 482; https://doi.org/10.3390/cancers11040482
Received: 18 March 2019 / Revised: 1 April 2019 / Accepted: 2 April 2019 / Published: 4 April 2019
(This article belongs to the Collection Drug Resistance and Novel Therapies in Cancers)
Surgical resection is considered a standard therapy for malignant melanoma (MM). However, it has not yet been established as an optimal treatment strategy for gynecological MMs, particularly owing to their very low incidence rates. We retrospectively analyzed clinical outcomes of carbon-ion radiotherapy (C-ion RT) for gynecological MMs. The eligibility criterion was the presence of histologically confirmed gynecological MM. Patients with pelvic or inguinal lymph node metastases were included, while those with distant metastases were excluded. The pelvic and inguinal lymph node regions were irradiated with up to 36 gray relative biological effectiveness (Gy (RBE)) followed by a gross tumor volume boost of up to 57.6 Gy (RBE) or 64 Gy (RBE) in 16 fractions over 4 weeks. Thirty-seven patients (median age: 71 years) were examined. In total, 22 patients had vaginal tumors, 12 had vulval tumors, and 3 had cervical uterine tumors. The median follow-up periods were 23 months (range: 5–103 months) for all patients and 53 months (range: 16–103 months) for survivors. Thirty of 37 patients (81%) achieved complete tumor disappearance. The 2-year local control, overall survival, and progression-free survival rates were 71%, 53%, and 29%, respectively. C-ion RT may be a definitive treatment option for patients with gynecological MM. View Full-Text
Keywords: carbon-ion radiotherapy; gynecology; melanoma; long-term outcomes; particle beam therapy carbon-ion radiotherapy; gynecology; melanoma; long-term outcomes; particle beam therapy
Show Figures

Figure 1

MDPI and ACS Style

Murata, H.; Okonogi, N.; Wakatsuki, M.; Kato, S.; Kiyohara, H.; Karasawa, K.; Ohno, T.; Nakano, T.; Kamada, T.; Shozu, M.; The Working Group of Gynecological Tumors. Long-Term Outcomes of Carbon-Ion Radiotherapy for Malignant Gynecological Melanoma. Cancers 2019, 11, 482.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop